TruSight Oncology Platform Reagents

A set of NGS platform reagents for detecting cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included. Read More...
Select Product(s)

TruSight® Oncology Library Prep



TruSight Oncology DNA Library Prep



TruSight® Oncology RNA Library Prep



TruSight® Oncology Enrichment



Product Highlights

These enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. This methodology provides laboratories with a deep view into the genetics of cancer.

  • Accurate Results from Low-Quality Samples1
    Enables variant detection with as little as 40 ng DNA and RNA input, maximizing the results from precious formalin-fixed, paraffin-embedded (FFPE) samples.
  • Supports Comprehensive Coverage of Cancer-Related Variants
    Allows the assessment of multiple variant types in one assay using DNA and RNA which creates efficiencies in sample usage, time, and cost.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.
  • Flexible Applications
    Enrichment-based workflow allows for a wide variety of content, input types, and applications.

See the Entire TruSight Oncology Product Family

Frequently Purchased Together


Method-Specific Workflow Example


Related Products

TruSight Oncology 500

Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Oncology 500 ctDNA

Assay targeting multiple somatic variant types from plasma, including microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.

  1. Data on file. Illumina, Inc. March 2017.